Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5O2S.Na |
| Molecular Weight | 176.168 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)C1=C(S)C=CC=C1
InChI
InChIKey=HBAIZOJDXAXWHS-UHFFFAOYSA-M
InChI=1S/C7H6O2S.Na/c8-7(9)5-3-1-2-4-6(5)10;/h1-4,10H,(H,8,9);/q;+1/p-1
| Molecular Formula | C7H5O2S |
| Molecular Weight | 153.178 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thiosalicylic acid is an analgesic and anti-inflammatory agent. It is used (in form of sodium salt) to relieve symptoms of acute gout, painful musculoskeletal conditions, osteoarthritis and rheumatic fever. The drug exerts its action by inhibiting prostaglandin synthesis. Thiosalicylic acid usage is associated with the risk of contact dermatitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
| Primary | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cytotoxicity of Triorganophosphinegold(I) n-Mercaptobenzoates, n = 2, 3 and 4. | 2002 |
|
| Using model complexes to augment and advance metalloproteinase inhibitor design. | 2004 May 17 |
|
| Self-assembly of dialkyltin moieties and mercaptobenzoic acid into macrocyclic complexes with hydrophobic "pseudo-cage" or double-cavity structures: supramolecular infrastructures involving intermolecular C-H...S weak hydrogen bonds and pi-pi interactions. | 2005 Dec 23 |
|
| Quantitative description of the deactivation channels of the first excited singlet state of 2- and 4-thiosalicylic acids. | 2005 Jul 28 |
|
| Determination of mercury complexation in coastal and estuarine waters using competitive ligand exchange method. | 2005 Sep 1 |
|
| Effect of subinhibitory concentration of some established and experimental antifungal compounds on the germ tube formation in Candida albicans. | 2007 |
|
| In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols. | 2008 Apr 30 |
|
| Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries. | 2008 Aug |
|
| Determination of acrylamide during roasting of coffee. | 2008 Aug 13 |
|
| Development of a stable isotope dilution assay for the quantitation of glycidamide and its application to foods and model systems. | 2008 Aug 13 |
|
| Synthesis and biological evaluation of sulfur-containing cinnamate and salicylate derivatives. | 2008 Mar |
|
| Zinc ions cause the thimerosal-induced signal of fluorescent calcium probes in lymphocytes. | 2009 Feb |
|
| [1,2-Bis(diphenyl-phosphino)ethane-κP,P'](2-carboxyl-atothio-phenolato-κO,S)nickel(II) methanol solvate. | 2009 Jan 8 |
|
| Ultrasonic-assisted precolumn derivatization-HPLC determination of acrylamide formed in Radix Asparagi during heating process. | 2009 May 1 |
|
| Synthesis and characterization of thiosalicylic acid stabilized gold nanoparticles. | 2009 Sep 15 |
|
| Electrochemical scanning tunneling spectroscopy of redox-active molecules bound by Au-C bonds. | 2010 Mar 3 |
|
| 2-[(2-Carboxy-phen-yl)disulfan-yl]benzoic acid-4,4'-bipyridyl N,N'-dioxide (1/2). | 2010 May 26 |
|
| 14-(1,3-Benzodioxol-5-yl)-7,14-dihydro-dibenzo[a,j]acridine. | 2010 Nov 6 |
|
| Low molecular weight thiols reduce thimerosal neurotoxicity in vitro: modulation by proteins. | 2010 Oct 29 |
|
| Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. | 2010 Oct-Dec |
Sample Use Guides
Acute gout: initial dose is 100 mg every 3 to 4 hours for 2 days, then 100 mg daily. Painful musculoskeletal conditions: 50 to 100 mg daily or every other day. Osteoarthritis: 10 mg 3 times/week for several weeks then once a week, usually up to a total dosage of 2.5 g. Rheumatic fever: initial dose is 100 to 150 mg every 4 to 8 hours for 3 days, then 100 mg two times daily.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:19:20 GMT 2023
by
admin
on
Fri Dec 15 15:19:20 GMT 2023
|
| Record UNII |
C2D9ITW04B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4856
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
SUB15331MIG
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
C2D9ITW04B
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
C87326
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
91100
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000078126
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
134-23-6
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
23681689
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY | |||
|
DTXSID90928380
Created by
admin on Fri Dec 15 15:19:20 GMT 2023 , Edited by admin on Fri Dec 15 15:19:20 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |